Leerink Partners analyst Stephanie Davis maintained a Buy rating on Veeva Systems (VEEV – Research Report) today and set a price target of $268.00. The company’s shares closed last Friday at $187.69, close to its 52-week low of $185.12.
According to TipRanks.com, Davis is a 3-star analyst with an average return of 2.6% and a 51.9% success rate. Davis covers the Technology sector, focusing on stocks such as Computer Programs and Systems, Tabula Rasa HealthCare, and Nuance Communications.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Veeva Systems with a $260.38 average price target, representing a 35.3% upside. In a report issued on March 3, FBN Securities also maintained a Buy rating on the stock with a $250.00 price target.
Based on Veeva Systems’ latest earnings release for the quarter ending January 31, the company reported a quarterly revenue of $485 million and net profit of $97.1 million. In comparison, last year the company earned revenue of $397 million and had a net profit of $103 million.
Based on the recent corporate insider activity of 113 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VEEV in relation to earlier this year. Most recently, in December 2021, Ronald Codd, a Director at VEEV sold 11,625 shares for a total of $3,034,706.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 2007 and headquartered in California, Veeva Systems, Inc. is a leader in cloud-based software for the global life sciences industry. Its solutions are focused on pharmaceutical and life sciences industry applications.
Read More on VEEV:
- Analysts’ Top Healthcare Picks: Fulcrum Therapeutics (FULC), Treace Medical Concepts (TMCI)
- Evercore ISI Believes Nextier Oilfield Solutions (NEX) Won’t Stop Here
- Evercore ISI Maintains a Hold Rating on Canadian Natural (CNQ)
- EPAM to Discontinue Services in Russia
- Stellantis (STLA) Gets a Hold Rating from RBC Capital